Clinical studies showed that HDC/LD-IL-2 significantly and sustainably improved leukemia-free survival with a good safety profile, and that patients less than 60 years old in CR after one induction and/or with a normal karyotype would particularly benefit from the association. Here, IL2 is linked to leukemia.